Abstract
In July 2013, the Secretary of Health amended the National Organ Transplant Act of 1986 to designate vascularized composite tissue allografts (VCAs) as organs. The definition of a VCA as an organ required that all nine criteria published in the Final Rule were fulfilled. VCAs meeting the definition of an organ would henceforth come under the oversight of the Organ Procurement Transplant Network (OPTN) and were required to develop and be in compliance with policies and bylaws as for traditional organ transplantation. The implementation date for the Final Rule modification was July 3, 2014. The OPTN and the United Network of Organ Sharing (UNOS) convened a multidisciplinary VCA committee to spearhead developing the first policies relevant to VCA. Described in this article are the policies that have been developed and the necessary bylaw changes required. These include requirements for OPTN/UNOS membership for VCA programs, specific policies for the authorization of potential donors of VCAs, allocation algorithms for VCA donors, mandatory data submission requirements, and guidance documents for the donation and authorization process, and for potential VCAs from living donors. The OPTN/UNOS Board approved the initial policies and bylaw changes in June 2014 to meet the deadline for implementation of the Final Rule modification. Since then, further modifications of the first policies and bylaws have occurred which are also described.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Glazier AK. Regulatory face-off: what agency should oversee face transplants? Am J Transplant. 2008;8:1393–5. This commentary sets the stage for the rationale for the OPTN to be the best suited regulatory agency to oversee face transplantation specifically and VCAs in general.
US Federal Register. 73(42), 2008.
42 CFR Part 121, as amended July 3, 2013. This is the description of the Final Rule amending the National Organ transplant Act that allowed VCAs to be included in the definition of an organ. The Secretary of Health’s rationale for the decision, including public comment and her response is included.
Brännström M, Johannesson L, Bokström H, et al. Livebirth after uterus transplantation. Lancet. 2015;385(9968):607–16. This study summarizes the development of a living donor uterus program, including the large animal studies that resulted in the first successful live birth from a uterus donated by a living donor.
Hazani R, Coots BK, Buntic RF. Bilateral breast reconstruction: the simultaneous use of autogenous tissue and identical twin isograft. Ann Plast Surg. 2009;63(5):496–8.
http://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_14 Accessed 04 Dec 2015.
http://optn.transplant.hrsa.gov/resources/by-organ/vascular-composite-allograft/vcas-from-living-donors/ Accessed 04 Dec 2015.
http://optn.transplant.hrsa.gov/media/1137/vca_donor_guidance.pdf Accessed 04 Dec 2015.
Tintle SM, Levin LS. The reconstructive microsurgery ladder in orthopaedics injury. Int J Care Inj. 2013;44(3):376–85.
Haddock NT, Chang B, Bozentka DJ, Steinberg DR, Levin LS. Technical implications in proximal forearm transplantation. Tech Hand Upper Extrem Surg. 2013;17(4):228–31.
Tintle S, Potter BK, Elliott RM, et al. Hand transplant. J Bone Joint Surg. 2014;2(1):e1–9. This paper provides an overview of the state of the art of hand transplantation.
Levin LS. The American Society for Surgery of the Hand Council: ASSH position statement on hand transplantation. J Hand Surg. 2013;38A(11):2234–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
S.V. McDiarmid and Richard S. Luskin declare that they have no conflict of interest.
L. Scott Levin reports grants from the Department of Defense, other from Hansjorg Wyss Fund, and royalties from Mavrek, Inc. In addition, Dr. Levin has a patent with Sternal Talon with paid royalties.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on OPTN Policy
Rights and permissions
About this article
Cite this article
McDiarmid, S.V., Levin, L.S. & Luskin, R.S. Vascularized Composite Tissue Allografts (VCA): the Policy Side. Curr Transpl Rep 3, 50–56 (2016). https://doi.org/10.1007/s40472-016-0094-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40472-016-0094-9